Products are not for human consumption and are not intended for diagnostic, therapeutic, or medical use
Oher GLP-1 like lixsenatide (Sanofi Aventis, trade name Lyxumia) and albiglutide (GlaxoSmithKline, trade names Epezan and Tanseum) are currently approved or are under consideration for diabetes treatment (Ladenheim, 2015)
There is also a deeper pharmaceutical and patent strategy behind this move
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management
Fibromyalgia Affecting over four million people in America alone, fibromyalgia is a common condition that causes widespread musculoskeletal pain, distress, and muscle weakness
Have allergies or prior reactions to injections, vitamins, preservatives, or medications